1 week Ago By [email protected] (MENAFN)
Shrewsbury, MA, March 24, 2025 – SignaBlok, Inc., a preclinical stage biotechnology company pioneering first-in-class, new mechanism-based peptide therapies for multiple diseases, today announced it will present positive preclinical data detailing therapeutic activity of its leading macrophage-restricted TREM-1 inhibitor in experimental sepsis, acute respiratory distress syndrome (ARDS), and pulmonary fibrosis (PF) at the RIS and ATS Conference in San Francisco, California from May 16-21, 2025. Details on SignaBlok's upcoming 2025 RIS and ATS poster presentations are as follows: .
In septic animals, TREM-1 blockade by SignaBlok's first-in-class macrophage-restricted TREM-1 inhibitor protects from death with the level of protection not declining at delayed treatment times . In rats, macrophage-restricted TREM-1 blockade significantly reduces lipopolysaccharide (LPS)-induced neutrophil accumulation in the lungs when injected after, but not before, LPS challenge . In mice with bleomycin-induced pulmonary fibrosis,TREM-1 blockade reduces the rate of progression and reverses fibrosis in the prevention and treatment models .
Data highlight potential of SignaBlok's SCHOOL technology platform to support clinical development of TREM-1 drug with minimal risk of failure due to a new mechanism of action Respiratory Innovation Summit: Poster Title: Sepsis: Understanding Nature. Solving the Inflammation Puzzle. Saving Lives.
Presenter: Alexander B. Sigalov, Ph.D.
(SignaBlok President and Principal Investigator) Date / Time: Friday May 16, 2025 2 PM - Saturday May 17, 2025, 6 pm ATS International Conference: Poster Title: Ligand-Independent TREM-1 Blockade Ameliorates Pulmonary Inflammation and Fibrosis Presenter: Alexander B. Sigalov, Ph.D.
(SignaBlok President and Principal Investigator) Abstract Presentation Number: 9150 Session: A22 – Break on through: Airway epithelial barrier in inflammation and injury Date / Time: Sunday May 18, 2025, 9:15 am – 11:15 am About TREM-1 Triggering receptor expressed on myeloid cells 1 (TREM-1) serves as an inflammation amplifier. As such, TREM-1 is involved in the pathogenesis of sepsis, ARDS, PF, and other inflammatory pathologies. Clinical targeting of TREM-1 is challenging due to multiple known and still unidentified TREM-1 ligands.
About SignaBlok SignaBlok, Inc. is a Massachusetts-based biotechnology company founded in 2009 to develop innovative, first-in-class therapeutics for targeted treatment of inflammation-associated diseases through the use of two key SignaBlok's proprietary technologies: 1) new mechanism-based approach to inhibition of cell receptors by using innovative, ligand-independent inhibitory peptides (the so-called SCHOOL peptides, the abbreviation coming from the "Signaling Chain HOmoOLigomerization" model of immune signaling); and 2) nature-inspired, multifunctional nanotechnology for targeted drug and/or imaging agent delivery to macrophages. Additional information about SignaBlok is available at MENAFN26032025003520003262ID1109357558 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind.
We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above..
